
Embody is receiving a $2.5 million Phase II Small Business Innovation Research award through the Defense Advanced Research Projects Agency (DARPA), bringing its total DARPA funding to $14.35 million. The award will support development and clinical assessment of MICROBRACE™ ACL technology for anterior cruciate ligament repair.
MICROBRACE for ACL is a stand-alone, off-the-shelf solution designed to immediately restore mechanical stability to the knee joint and gradually remodel over time.
“A collagen implant that provides strength long enough to protect a surgical repair or reconstruction yet remodels over time is quite desirable. There are numerous potential applications for the Embody MICROBRACE including ACL surgery,” commented Kevin F. Bonner, M.D., an orthopedic surgeon and Director of the Research Foundation at The Jordan-Young Institute in Virginia Beach, Virginia.
Embody is developing biomaterials with an initial focus on orthopedic applications such as Achilles, rotator cuff and knee ligament repair. Previously, the company has raised funding from cultivate(MD) and DARPA.
Embody is receiving a $2.5 million Phase II Small Business Innovation Research award through the Defense Advanced Research Projects Agency (DARPA), bringing its total DARPA funding to $14.35 million. The award will support development and clinical assessment of MICROBRACE™ ACL technology for anterior cruciate ligament repair.
Embody is receiving a $2.5 million Phase II Small Business Innovation Research award through the Defense Advanced Research Projects Agency (DARPA), bringing its total DARPA funding to $14.35 million. The award will support development and clinical assessment of MICROBRACE™ ACL technology for anterior cruciate ligament repair.
MICROBRACE for ACL is a stand-alone, off-the-shelf solution designed to immediately restore mechanical stability to the knee joint and gradually remodel over time.
“A collagen implant that provides strength long enough to protect a surgical repair or reconstruction yet remodels over time is quite desirable. There are numerous potential applications for the Embody MICROBRACE including ACL surgery,” commented Kevin F. Bonner, M.D., an orthopedic surgeon and Director of the Research Foundation at The Jordan-Young Institute in Virginia Beach, Virginia.
Embody is developing biomaterials with an initial focus on orthopedic applications such as Achilles, rotator cuff and knee ligament repair. Previously, the company has raised funding from cultivate(MD) and DARPA.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.